Alx Oncology Holdings (ALXO) Short term Debt (2020 - 2026)

Alx Oncology Holdings (ALXO) has 7 years of Short term Debt data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 200.0% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (up 200.0% YoY), and the FY2025 full-year result was $5.2 million, up 1099.31% from the prior year.
• Short term Debt steadied at $5.2 million in Q1 2026, from $5.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.2 million in Q4 2025 to a low of $435000.0 in Q4 2024.
• A 5-year average of $2.8 million and a median of $2.6 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt gained 1.23% in 2022 and jumped 1099.31% in 2025, its largest moves.
• Tracing ALXO's Short term Debt over 5 years: stood at $1.6 million in 2022, then plunged by 49.7% to $830000.0 in 2023, then plunged by 47.59% to $435000.0 in 2024, then jumped by 1099.31% to $5.2 million in 2025, then changed by 0.0% to $5.2 million in 2026.
• Business Quant data shows ALXO's Short term Debt at $5.2 million in Q1 2026, $5.2 million in Q4 2025, and $4.3 million in Q3 2025.